ClinicalTrials.gg

Program

votoplam

Also written as “Votoplam (blinded)”, “PTC518” and “Votoplam”.

In Novartis's pipeline, Huntingtin modulator. Its studies are mostly in Huntington Disease, led by Novartis.

Furthest: phase 3, since Jan 7, 20263 company-led studies, 2 open or runningNext primary completion: Jul 16, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis32 open or runningphase 3since Jan 7, 2026Apr 27, 2022Jul 16, 2029phase 2 · NCT06254482
  • Named in Novartis’s own pipeline as HTT227 (votoplam), phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2022First study: phase 2 study in Huntington DiseaseFirst studyNCT05358717 · 159 enrolled · United States, Australia, Austria and more
  2. Feb 2, 2024Phase 2 study in Huntington DiseaseNCT06254482 · 144 enrolled · Australia, Austria, Canada and more
  3. Jan 7, 2026Phase 3 study in Huntington DiseasePhase 3 reachedNCT07326709 · 770 planned · United States, Argentina, Australia and more

Ahead

  1. Jul 16, 2029Primary completion: phase 2 study in Huntington DiseaseNCT06254482
  2. Apr 2, 2030Primary completion: phase 3 study in Huntington DiseaseNCT07326709

TargetBeta

“Huntingtin modulator”the company's pipeline, read by Claude · source

Other programs on HTT

ProgramCompanyFurthest phaseStudies
L-(+)-methylenetetrahydrofolic acidruleisofol-medical-abphase 35
SKY-0515ruleskyhawk-therapeutics-incphase 32

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07326709Huntington Disease · United States, Argentina, Australia and more3RecruitingApr 2, 2030770
NCT06254482Huntington Disease · Australia, Austria, Canada and more2Active, not recruitingJul 16, 2029144
NCT05358717Huntington Disease · United States, Australia, Austria and more2CompletedFeb 7, 2025159

How it is read

Names in the registry

  • “Votoplam (blinded)”, 1 entry
  • “PTC518”, 1 entry
  • “Votoplam”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.